PharmaPoint: Macular Edema and Macular Degeneration - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Macular Edema and Macular Degeneration - Japan Drug Forecast and Market Analysis to 2023 is a new market research publication announced by Reportstack. Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Japan has an increasingly aging society, which will act as a significant driver of growth in this market, along with the introduction of novel therapies for both wet and dry AMD. The wAMD drugs, Fovista and abicipar pegol, are expected to enter the Japanese AMD market in 2019 and 2023, respectively, while the dAMD drugs, lampalizumab and emixustat, are both expected to enter in 2018.

To view the table of contents and know more details please visit PharmaPoint: Macular Edema and Macular Degeneration - Japan Drug Forecast and Market Analysis to 2023.


- Overview of Macular Edema and Macular Degeneration including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Macular Edema and Macular Degeneration market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in Japan.

About Reportstack:

Reportstack  is one of the leading distributors of market research reports in the world today. We host more than 200,000 research products from the world's top publication houses. These publications are distributed amongst 12 top industry verticals and 62 sub verticals, which are then further classified into 257 business categories and 5000 micro markets. The vast selection criterion provides granular data from the length and breadth of all these industries delivering Reportstack  members with cutting edge research products to facilitate strategic business decisions.


Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research